Nov 27 2023, 09:22
5 MNC pharma stocks with upside up to 21%:
There was a time when having MNC stock was a must have in one's portfolio. They reason, they were very liberal at giving bonuses, dividend payments were good and given the fact some of them actually owned the best of the brands, they had seen a secular growth, which meant they were also able to deliver decent returns to shareholders. After the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the street.
There are many reasons for this, firstly a number of Indian companies have upped their corporate governance standard, some on their own, some due to regulatory changes. Over a period of time this meant that, the focus on MNC stocks came down and except in exceptional cases of FMCG sector, the interest of the street has been reducing with every passing year.
There are multiple reasons for this decline in interest, there have been some MNC companies which had taken Indian investors for a ride when there was any merger and acquisition at global level.
In some cases, in the capital goods sector, restructuring was done in a manner in which part of the Indian company was sold to the parent company much below what it would have fetched if sold to any other bidder. Some did buy backs for delisting which were much below what they should have offered.
The stocks collated with data from the latest Stock Reports dated Nov 25h, 2023.
MNC Pharma - Upside potential
Nov 24, 2023
Company Name
Pfizer
Avg Score
6
Reco
Strong Buy
Analyst Count
6
Upside Potential%
21.6
Inst Stake %
16.0
Market Cap Type
Mid
18,613
Market Cap Rs Cr
Company Name
Avg Score
Reco
Analyst Count
Upside Potential%
Abbott India
6
Buy
8
21.4
Inst Stake %
7.5
Market Cap Type
Large
Market Cap Rs Cr
51,114
Company Name
Sanofi India
Avg Score
6
Reco
Buy
Analyst Count
8
Upside Potential%
14.3
Inst Stake %
25.3
Market Cap Type
Mid
Market Cap Rs Cr
18,489
Company Name
Procter & Gamble Health
Avg Score
7
Reco
Analyst Count
Upside Potential%
1.7
Inst Stake %
14.2
Market Cap Type
Mid
Market Cap Rs Cr
8,555
Company Name
GlaxoSmithKline Pharma
Avg Score
7
Reco
Hold
Analyst Count
6
* Upside Potential%
1.5
Inst Stake%
10.9
Market Cap Type
Large
Market Cap Rs Cr
27,867
Calculated from highest price target given by analysts
source: et
Nov 27 2023, 15:56